upregulates expression of ␥-glutamylcysteine synthetase in pulmonary artery endothelial cells.
reactive oxygen species; Nrf-1 and -2; nuclear factor-B; antioxidant response element; mitogen-activated protein kinase BLEOMYCIN IS PRIMARILY USED for the treatment of testicular carcinoma, lymphoma, and squamous cell carcinoma, but its use as a chemotherapeutic agent is limited by adverse side effects, especially pulmonary injury and fibrosis. Because of this, bleomycin has been used to develop a rodent experimental model of pulmonary fibrosis that has allowed the study of changes in the cellular composition of the lung and the expression of specific proteins leading to fibrosis. Many changes identified in the bleomycin model system have also been observed in pulmonary fibrosis induced by other causes (2, 20, 21, 30) . Treatment of rodents with bleomycin endotracheal instillation or subcutaneous injection results in initial pulmonary inflammation and a spike of epithelial/endothelial apoptosis (13, 30, 38, 46) . This is followed by the proliferation of myofibroblasts (fibroblasts expressing ␣-smooth muscle actin) and sustained epithelial/endothelial apoptosis. The bleomycin model has allowed the identification of potentially critical changes in protein expression, including the induction of transforming growth factor-␤1 (18, 26, 27, 29, 30) . However, the signaling mechanism(s) inducing these changes is not well understood.
Bleomycin triggers apoptosis in growing cells by causing single-and double-stranded DNA breaks through the direct binding of bleomycin to DNA. This activity is dependent on oxygen and a bound ferrous ion. Bleomycin is also believed to produce reactive oxidative species (ROS), including superoxide, H 2 O 2 , and/or organoperoxides, which may also play a role in the toxicity of bleomycin (34) . Several studies have shown that cells are partially protected from the cytotoxic effects of bleomycin by acute hypoxia (thus eliminating the oxygen source for ROS) or by the addition of superoxide dismutase enzyme or transfection with an expression vector for superoxide dismutase (thus reducing the level of ROS generated by bleomycin) (10, 34) . In contrast, the detrimental effects of bleomycin can be intensified via reduction of the intrinsic cellular defenses against oxidative stress. Either buthionine sulfoximine (BSO)-induced depletion of cellular glutathione (GSH) or the lack of GSH S-transferase (a phase II detoxifying enzyme) results in hypersensitivity of cells to bleomycin-induced apoptosis (12, 31) .
On the basis of studies indicating that bleomycin cytotoxicity may be modulated by oxidants and antioxidants, we hypothesized that bleomycin may regulate cellular defenses against oxidative stress. GSH is a ubiquitous sulfhydryl-containing tripeptide that serves as a primary biological defense against oxidative damage (6, 33, 37, 44) . GSH, normally present in cells at millimolar levels, directly interacts with ROS and toxins during cellular detoxification (6, 37, 44) . Adaptation of cells to oxidative stress can occur via the induction of antioxidant enzymes and increased cellular levels of GSH. The enzyme ␥-glutamylcytsteine synthetase (␥-GCS) controls the rate-limiting step in GSH synthesis (16, 17, 24) . This enzyme is composed of two subunits, a catalytic heavy chain (␥-GCS h ) and a regulatory light chain. Both ␥-GCS subunits have been shown to be upregulated in response to oxidative stress, including ionizing radiation, ROS, heavy metals, phenolic antioxidants, and the GSH-depleting compound BSO (16, 17, 32, 33, 36, 41, 44) . The regulation of the ␥-GCS subunits by oxidative stress has been demonstrated in variety of species, including human, rat, and bovine (32, 33, 36, 44) .
In the present study, we examined the effect of bleomycin on the regulation of GSH in bovine pulmonary artery endothelial cells (BPAEC). Our results indicate that bleomycin treatment increases total cellular levels of GSH and upregulates the level of ␥-GCS h mRNA. We also show that bleomycin activates the DNA binding activity of nuclear factor (NF)-B and Nrf-1 and -2 transcription factors. These factors are known to be activated by oxidative stress and to regulate the expression of human ␥-GCS h (14-17, 24, 40, 41, 44, 45) .
EXPERIMENTAL METHODS
Reagents. Bleomycin (Blenoxane) was from Mead Johnson (Princeton, NJ). The mitogen-activated protein kinase/extracellular signal-regulated kinase [MAPK/ERK (MEK)] 1/2 inhibitor U-0126 was purchased from New England Biolabs (Beverly, MA). Other reagents are described below.
Cell culture and bleomycin treatment. BPAEC were obtained from freshly slaughtered calves as previously described (4) . Passage 3-8 cells were used for all experiments. Rat pulmonary microvascular endothelial cells (RPMEC) were a gift of Dr. Una Ryan (Avant Immunotherapeutics, Needham, MA) (3); these cells were used as a control in Fig.  2 . Both BPAEC and RPMEC were cultured in RPMI 1640 (GIBCO-BRL, Rockville, MD) with antibiotics (penicillin and streptomycin), fungisone, and 10% fetal bovine serum in 5% CO 2 at 37°C in a humidified atmosphere. For cell culture treatment, bleomycin was dissolved in 0.9% NaCl and added to the culture medium.
Propidium iodide staining and fluorescence activated cell sorting. Propidium iodide and fluorescence-activated cell sorting (FACS) were used to determine cellular apoptosis. Cells (ϳ3-7.5 ϫ 10 5 ) were washed twice with phosphatebuffered saline (PBS) at 25°C and trypsinized. Cells were then pelleted by centrifugation and washed twice on ice with cold PBS. After the last wash, we resuspended cell pellets in 100 l of cold PBS, and added 1 ml of cold 80% ethanol dropwise while vortexing on a low setting. Ethanol-treated cells were stored at 4°C for at least 4 h and up to 1 wk. Before FACS analysis, cells were pelleted at 4°C, resuspended in 0.5 ml of propidium iodide solution [0.05 mg/ml RNase A in PBS containing 5% (wt/vol) propidium iodide], and incubated for 30 min on ice in the dark. Cells were then analyzed on a Becton-Dickinson FACS Calibur (Franklin Lakes, NJ) cell sorter.
Cell counts and preparation for GSH assays. Cell counts and GSH assays were performed as described (43) . Culture dishes were rinsed twice with PBS at 25°C and incubated for 3-5 min with 1.0 ml of trypsin-EDTA. The cells were rapidly suspended and placed on ice. The cellular suspension (0.1 ml) was removed, diluted, and counted on a ZM Coulter Counter (Coulter Electronics, Hialeah, FL). Of the remaining suspension, 0.8 ml was treated with 0.1 ml of 1% perchloric acid. Lysates were sonicated on ice for 10 s and centrifuged at 14,000 g at 4°C for 20 min. Aliquots were stored at Ϫ20°C for GSH assays.
GSH assay. GSH assays were performed as specified (40) . Frozen perchloric acid-treated supernatants were thawed on ice and sonicated for 10 s on ice. The pH was adjusted to 7.0 with 0.3 M potassium hydroxide-3-(N-morpholino)propanesulfonic acid (MOPS). The sonicate was then centrifuged at 14,000 g at 4°C for 20 min. The supernatant was assayed for total cellular GSH by the spectrophotometric Tietze method (1) . Briefly, the sum of the oxidized and reduced forms of GSH was determined using a kinetic assay in which GSH or GSH disulfide and GSH reductase reduce 5,5Ј-dithiobis(2-nitrobenzoic acid) to form 5-thio-2-nitrobenzoate (TNB). The formation of TNB was followed spectrophotometrically at 412 nm. Each assay was individually calibrated with standard GSH, and the concentration of each sample was adjusted by dilution to ensure that the reaction rate was on the linear portion of the standard curve. Cellular GSH levels were expressed as nanomoles per 10 6 cells. For the assay, brewer's yeast GSH reductase, ␤-NADPH, and GSH disulfide were obtained from Sigma (St. Louis, MO).
RNA purification and Northern blot. RNA was purified using Trizol (GIBCO-BRL) according to the manufacturer's instructions; RNA concentrations were determined by absorbance at 260 nm. RNA (10 g) was denatured in a loading buffer [0.4 M MOPS, pH 7.0, 2.5% formaldehyde, 67% formamide, 0.2 g ethidium bromide, 1.2 mM EDTA, 6.7 mM Na acetate, and 13% dye (50% glycerol, 1 mM EDTA, 0.25% bromophenol blue, and 0.25% xylene cyanol FF)] for 15 min at 65°C. Denatured RNA was run in a 0.9% (wt/vol) denaturing agarose gel (0.2 M MOPS, pH 7.0, 5 mM sodium acetate, 1 mM EDTA, and 1.8% formaldehyde) with running buffer (0.2 M MOPS, pH 7.0, 5 mM Na acetate, 1 mM EDTA, and 1.8% formaldehyde). RNA was transferred to a Zeta Probe blotting membrane (Bio-Rad, Hercules, CA) using capillary blotting in 1ϫ SSC (20ϫ SSC ϭ 3 M NaCl, 3 mM sodium citrate, pH 7.0). Blots were baked at 80°C for 2 h under vacuum and prehybridized in ExpressHyb (Clontech, Palo Alto, CA) for 30 min at 68°C under shaking. The 2 ϫ 10 6 counts ⅐ min Ϫ1 ⅐ ml Ϫ1 of labeled, denatured probe were then added with denatured salmon sperm DNA (100 ng/ml) to the prehybridized blot. Hybridization was performed at 68°C overnight with agitation. Blots were washed at 37°C; the first wash was performed in triplicate (2ϫ SSC and 0.05% SDS) for 15 min each; the second wash was done twice (1ϫ SSC and 0.1% SDS) for 15 min each at 50°C. The blot was then exposed to Kodak X-OMAT AR film (NEN, Boston, MA) at Ϫ80°C using intensifying screens.
The probe for human ␥-GCSh was the gift of Dr. Takahito Kondo (Nagasaki University School of Medicine, Nagasaki, Japan); this probe hybridizes strongly to human, mouse, and rat ␥-GCSh mRNA (16) . To produce labeled probes, we incubated 10-20 ng of the excised ␥-GCSh cDNA with 1ϫ hexanucleotide mix (Boehringer Mannheim, Indianapolis, IN), 0.05 mM dATP, dTTP, and dGTP, and 50 Ci ␣-[
32 P]dCTP for 1 h at 37°C. The labeled probe was purified from unincor-porated ␣-[ 32 P]dCTP using Sephadex G-50 Quick Spin columns (Boehringer Mannheim).
Electrophoretic mobility shift assay. Electrophoretic mobility shift assay (EMSA) was performed as described by Garner and Revzin (11) . To prepare nuclear extracts, cells were washed in PBS and incubated in 10 mM HEPES (pH 7.8), 10 mM KCl, 2 mM MgCl 2, 0.1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 5 g/ml leupeptin, 10 g/ml aprotinin, 1 mM NaF, 0.1 mM sodium orthovanadate, and 1 mM tetrasodium pyrophosphate for 15 min at 4°C. (Octylphenoxy)polyethoxyethanol (Igepal CA-630, Sigma) was then added at a final concentration of 0.6%(vol/vol). Samples were vortexed and centrifuged. Pelleted nuclei were resuspended in extraction buffer [50 mM HEPES (pH 7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 0.1 mM PMSF, 5 g/ml leupeptin, 10 g/ml aprotinin, 1 mM NaF, 0.1 mM sodium orthovanadate, 1 mM tetrasodium pyrophosphate, and 1% (vol/vol) glycerol], then mixed vigorously for 20 min, and centrifuged for 5 min. The supernatants were harvested, and protein concentrations were determined (22) .
Oligonucleotides containing the sense and antisense antioxidant response element (ARE) consensus sequence were 5Ј-TCACAGTGACTCAGCAGAATC-3Ј and 5Ј-GATTCTGCT-GAGTCA-CTGTGA-3Ј, respectively. [The ARE consensus sequence is underlined; the ARE sequence used is identical to ARE4 of the human ␥-GCS promoter (25, 42) .] Oligos were made 5 M in H2O, heated to 80°C for 20 min, and allowed to anneal by cooling slowly to ambient temperature. The double-stranded oligonucleotide probe containing consensus B sequence was 5Ј-GAT CCG AGG GGA CTT TCC GCT GGG GAC TTT CCA GG-3Ј. To perform EMSA, we incubated binding reaction mixtures containing 2 g protein of nuclear extract, 1 g poly(dI-dC) ⅐ poly(dI-dC), and 32 P-labeled double-stranded ARE or B oligonucleotide in 100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 10% (vol/vol) glycerol, and 20 mM Tris ⅐ HCl (pH 7.5) for 20 min at 25°C. Electrophoresis of samples through a native 6% polyacrylamide gel (acrylamide-bis, 29:1) was followed by autoradiography. Supershift experiments were performed by incubating 2 g Nrf-1, Nrf-2, c-Jun, c-Fos, NF-B p65, or NF-B p50 antibody (Santa Cruz Biotech) in the binding reaction mixture for 1 h at 4°C before the addition of the 32 P-labeled oligonucleotide probe to start the binding reaction. All experiments were repeated at least three times.
Western blot analysis. To prepare lysates, cells were washed in PBS and solubilized with 50 mM HEPES solution (pH 7.4) containing 1% (vol/vol) Triton X-100, 4 mM EDTA, 1 mM NaF, 0.1 mM sodium orthovanadate, 1 mM tetrasodium pyrophosphate, 2 mM PMSF, 10 g/ml leupeptin, and 10 g/ml aprotinin. The lysate was cleared by centrifugation at 4°C for 15 min. Protein concentrations in the supernatant were determined as above (22) . Cell lysates (10 g protein) were electrophoresed through reducing (5% ␤-mercaptoethanol) SDS polyacrylamide-bis gels (10%) and electroblotted onto nitrocellulose membranes. After the transfer, membranes were blocked in 5% milk in Tween-and Tris-buffered saline (20 mM Tris ⅐ HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween 20) and then blotted with the antibody for the NF-B p65 subunit and IB␣ (Santa Cruz Biotech). Levels of proteins and phosphoproteins were detected with horseradish peroxidase-linked secondary antibodies and ECL System (Amersham Life Science, Arlington Heights, IL). Western blots were repeated at least three times.
Statistics. Statistical comparisons were performed using a Student's t-test for unpaired samples and a two-way analysis of variance for multiple comparisons. Statistical significance was determined at P Ͻ 0.05.
RESULTS

Bleomycin upregulates cellular GSH and the ␥-GCS
gene. Bleomycin has been shown to induce growth arrest, apoptosis, and necrosis in a number of cells, including immortalized cells and primary cancer cells (31, 34) . We first determined doses of bleomycin that induce growth arrest with limited cell death in BPAEC. Cells were placed in RPMI medium containing 0.1% FBS for 24 h and then exposed to increasing doses of bleomycin for 24 h. Cell numbers indicated that 10 g/ml of bleomycin induced high levels of growth arrest (Fig. 1A) , which was associated with visible cell death (data not shown). Levels of 1.0 and 0.1 g/ml of bleomycin induced lower levels of growth arrest. Propidium iodide staining and FACS analysis showed that 1.0 g/ml of bleomycin induced only 8.8% (Ϯ 1.6 SD) apoptosis, compared with 5.8% (Ϯ 1.7 SD) apoptosis in control cells (n ϭ 3).
Bleomycin is believed to induce oxidative stress on cells by the generation of ROS through a bound ferrous ion. GSH is a primary constituent for protecting cells against oxidative stress, and its formation can be upregulated by ROS-producing compounds (6, 32, 33, 44) . We analyzed total cellular GSH to determine whether bleomycin was able to regulate GSH formation. A spectrophotometric assay for total cellular GSH showed that both 0.1 and 1.0 g/ml of bleomycin caused approximately twofold increases within 18 h compared with control (Fig. 1B) . These results were comparable with the twofold increase in total cellular GSH induced by an 18-h treatment with 100 M H 2 O 2 , used as a positive control (43) .
The enzyme ␥-GCS controls the key regulatory step in the production of cellular GSH (6, 35, 44) . Northern blot analysis shows that ␥-GCS h mRNA levels are upregulated by bleomycin in BPAEC. Figure 2A is a representative time course in which ␥-GCS h mRNA is increased by 30 min in response to 1 g/ml of bleomycin. BSO, an agent known to induce ␥-GCS h expression, was used as a positive control (44) . Our probe for ␥-GCS h is based on rat cDNA, but the bovine size, sequence, and, therefore, complementarity to rat ␥-GCS h are not known. The rat mRNA was included as a positive control for the position of ␥-GCS h ( Fig. 2A) . Densitometry of the representative data showed that within 30 min, bleomycin caused a 1.5-fold increase in ␥-GCS h mRNA levels, whereas at 3-6 h bleomycin induced a 3-3.5-fold increase (Fig. 2C) . BSO exposure for 3 and 6 h induced a 2.5-and 2-fold increase in ␥-GCS h mRNA, respectively.
Bleomycin activates NF-B and the ARE-binding transcription factors Nrf-1 and -2. Studies of human
␥-GCS h gene expression have identified two promoter cis elements that are believed to primarily regulate its transcription: the B element and the ARE (6, 16, 17, 37, 44) . Increased expression of ␥-GCS h in response to ionizing radiation, which produces physical and chemical damage in addition to inducing the formation of ROS, is dependent on NF-B activation (16) . However, regulation of ␥-GCS h by xenobiotics and ROS-generating compounds is believed to occur through the activation of proteins that bind to the ARE (17, 37, 44) . Because bleomycin induces physical damage to cellular proteins and DNA while at the same time producing ROS, we investigated the activation of DNA binding to both B and ARE.
A time course of bleomycin treatment showed an increase in DNA-binding activity of NF-B within 1 h as monitored by EMSA (Fig. 3A) . Densitometric analysis showed that bleomycin induced an approximately fourfold increase in NF-B activation in 2 h. This increase in NF-B activity persisted for at least 24 h (data not shown). NF-B is activated in coordination with the degradation of its inhibitory subunit, IB. Western blots show that tumor necrosis factor-␣ induces rapid degradation of IB-␣ within 30 min in BPAEC, whereas bleomycin causes a more gradual degradation (Fig. 3B) . Western blots of NF-B p65 subunit were performed as a control, showing that levels of the transcription factor are unchanged by bleomycin treatment (Fig. 3B) . Supershift analysis of the NF-B band showed that both the p65 and p50 subunits are involved in the complex activated by bleomycin (Fig. 3C) .
A number of factors are believed to bind ARE and affect downstream transcription; these include the NF-E2-related factors (Nrf) 1 and 2, the Jun protein family (c-Jun, Jun-B, and Jun-D), c-Fos, and the Maf protein family (c-Maf, hMaf, MafG, and MafK) (7, 8, 14, 17, 23, 40, 41, 44) . Factor binding to the ARE increases with bleomycin treatment of BPAEC. EMSA experiments detected a Ͼ10-fold increase in the binding of factors to a consensus oligo for ARE, which was detected within 30 min of treatment with bleomycin and persisted for at least 24 h (Fig. 4) .
We performed supershift analysis to determine which protein(s) was activated in BPAEC by bleomycin. Preincubation of the nuclear extract with an antibodies specific for Nrf-1 and -2 decreases the density of the shifted 32 P-labeled ARE band (Fig. 5A) . Additionally, the Nrf-2 antibody causes the appearance of an ARE-containing band with increased electrophoretic mobility. These data indicate that the original EMSA band contains Nrf-1 and Nrf-2. Our results further suggest that the faster mobility EMSA band, which forms in the presence of the Nrf-2 antibody, contains another protein bound to the ARE. We have labeled this band ARE ϩ X. Importantly, the antibodies directed against Nrf-1 or -2 do not form complexes directly with the ARE in the absence of nuclear extract (Fig. 5A, lanes 2 and 3) . Previous reports have suggested that Nrf-2 may heterodimerize with c-Jun, JunD, MafG, and MafK; these proteins contain DNA-binding domains and are capable of directly binding the ARE (7, 15, 23, 44 ). An antibody directed against c-Jun did not result in any change in the ARE-containing band, suggesting that c-Jun is not activated by bleomycin and is not involved in Nrf-2 binding to the ARE (Fig. 5B) . Antibodies directed against c-Fos also caused no change in the ARE binding pattern; this factor is believed to be involved in the inhibition of transcription downstream of ARE (40) .
Bleomycin activates ARE-binding via ROS and NF-B via MAPK. Both ARE and NF-B site binding factors are known to be activated through a variety of signaling pathways (7, 8, 14, 28, 40, 41, 44, 45) . Both the overexpression of the ERK1-MAPK and the induction of ROS activate NF-B (16, 24, 28) . Studies have shown that Nrf-1 and -2 are activated in response to ROS, and the inhibition of ERK1/2-MAPK blocks activation of ARE-binding factors by xenobiotic compounds (17, 40, 44, 45) . We previously reported that bleomycin activates the ERK1/2 family of MAPKs (5), and it is widely believed that bleomycin produces ROS through its bound ferrous ion (10, 13, 34, 39 ). Thus we investigated whether one or both of these mechanisms downstream of bleomycin lead to the activation of factors that bind ARE and/or the NF-B site.
BPAEC were pretreated for 30 min with N-acetylcysteine (NAC), an antioxidant, or U-0126, an inhibitor of MEK1/2 (the kinase upstream of ERK1/2-MAPK). Cells were then treated with Ϯ 1.0 g/ml of bleomycin for 30 min, and nuclear extracts were prepared. EMSA shows that whereas NAC inhibited bleomycin activation of ARE-binding factors, U-0126 has no effect on the activation (Fig. 6A) . In contrast, U-0126 blocks bleomycin-induced NF-B activation, whereas NAC has little or no effect (Fig. 6B) . Pretreatment of cells with either NAC or U-0126 for 30 min blocks bleomycin upregulation of ␥-GCS h mRNA as determined by Northern blot analysis (Fig. 6C) . Fig. 4 . Bleomycin activates transcription factor binding to the antioxidant response element (ARE) consensus sequence. Confluent BPAEC were treated with 1 g/ml bleomycin for the indicated times. Nuclear extracts were incubated with the consensus oligonucleotide for ARE. The position of ARE is indicated with an arrow. EMSA experiments were repeated at least 3 times. Confluent BPAEC were treated with 1 g/ml bleomycin (Bleo) or 1 nM tumor necrosis factor (TNF)-␣ for the indicated times before purification of nuclear extracts. EMSA experiments were performed as described in EXPERIMENTAL METHODS. EMSAs were repeated at least 3 times. The position of NF-B is indicated. B: Western blots of cell lysates after treatment of BPAEC with 1 g/ml bleomycin or 1 nM TNF-␣ for the indicated times. Top: blotting with antibody directed against IB␣. Bottom: same samples blotted using an antibody directed against NF-B p65 subunit. C: supershifts of NF-B p65 and p50 subunits. Confluent BPAEC were treated with 1 g/ml bleomycin for 2 h. Nuclear extracts were incubated with 1 g of antibody against NF-B p65, NF-B p50, or both before EMSA was performed. Bleo, bleomycin.
DISCUSSION
The chemotherapeutic agent bleomycin can induce pulmonary fibrosis, thus limiting its application in cancer treatment in humans. This side effect has been utilized in an animal model system to identify cellular and molecular changes that occur during the development and progression of pulmonary fibrosis (10, 14, 18, 20, 21, 26, 27, 29, 30, 34, 38) . Despite extensive work demonstrating the changes in mRNA and protein expression that occur during bleomycin-induced fibrosis, comparatively little is known about the mechanism(s) of these events. The cytotoxic effects of bleomycin are modulated by antioxidants, and we hypothesized that bleomycin regulates cellular defenses against oxidative stress.
The present study indicates that in endothelial cell culture, treatment with sublethal levels of bleomycin (0.01-1.0 g/ml) for 18 h causes increased total cellular GSH. We also demonstrated that in 30 min, bleomycin increases the level of ␥-GCS h mRNA, the catalytic subunit of ␥-GCS that controls the key regulatory step in GSH synthesis. Karam et al. (19) previously reported a ϳ50% decrease in the level of total GSH in alveolar T2 cells isolated from Wistar rats treated for 7 or 14 days with bleomycin. This was accompanied by a slight decrease in ␥-GCS enzyme levels at 7 days. Further experiments are required to determine whether the increase in cellular GSH as observed in the present study would also occur in vivo after acute exposure to bleomycin. In response to oxidative or toxic stress, expression of the human ␥-GCS h is positively regulated at the level of transcription by factors binding to both ARE and NF-B promoter elements (16, 17, 40, 41, 44) . Our EMSA results indicate that bleomycin activates both ARE-binding factors and NF-B in BPAEC within 30 min. Although the sequence of the bovine ␥-GCS h promoter has not been reported, Shi et al. (32, 33) found that endogenous bovine ␥GCS h mRNA is increased in BPAEC in response to quinone-induced oxidative stress, similar to findings in other species, including human (44) . Therefore, in BPAEC, the induced increase of ␥-GCS h mRNA by bleomycin is consistent with a mechanism involving the induction of ARE-binding factors and NF-B.
A number of proteins have been shown to bind the ARE element, including Nrf-1 and -2 (members of the cap 'n' collar subfamily of basic region-leucine zipper transcription factors), members of the Jun family (c-Jun, JunB, and JunD), and several small Maf family proteins (c-Maf, hMaf, MafG, and MafK) (7, 8, 14, 17, 23, 40, 41, 44) . Supershift experiments using antibodies directed against Nrf-1 or Nrf-2 caused a reduction in the level of the ARE-containing band. However, neither the Nrf-1 nor -2 antibodies caused the appearance of a supershifted species, suggesting that these antibodies dissociate Nrf proteins from a complex with ARE. Inclusion of the antibody against Nrf-2 caused both the reduction of the original AREcontaining band and the appearance of a band with increased electrophoretic mobility. The induction of a band with faster mobility suggests that complexes with Nrf-2 contain at least one additional protein (X) and that the new, faster complex contains the ARE probe bound to X. The identity of X is currently unknown. Other laboratories have shown that Nrf-2 forms heterodimers with small Maf proteins, including MafG (7, 23, 44, 45) and Jun proteins (44) . Supershift experiments were performed using antibodies against c-Jun and c-Fos, but these antibodies did not alter the mobility of the ARE complex, indicating that these proteins are not activated by bleomycin.
Nrf proteins have been shown to be activated downstream of protein kinase C and the MAPKs ERK1/2 and stress-activated protein kinase/c-Jun NH 2 -terminal kinase (SAPK/JNK) (14, 44, 45) . In BPAEC, bleomycin activates p38/HOG1 (unpublished results) and ERK1/2 (5), but not SAPK/JNK (unpublished results). Our current data suggest that bleomycin activates Nrf-1 and -2 through a mechanism independent of ERK1/2-MAPK, as the MEK inhibitor U-0126 failed to block bleomycin induction. Our data showing the inhibition Nrf activation by NAC suggest that ROS act as second messengers downstream of bleomycin.
In contrast to Nrf-1 and -2 activation by bleomycin, NF-B activation is blocked by U-0126 but not by the ROS-quenching agent NAC, suggesting that the ERK1/ 2-MAPK pathway is involved. NF-B activation has been shown to occur in response to the overexpression of ERK1-MAPK (9, 28) .
In summary, our results indicate that bleomycin upregulates GSH and ␥-GCS through the activation of both ROS-and MAPK-dependent pathways in a mechanism that likely involves the induction of ARE-binding factors and NF-B. The use of bleomycin in animals remains the most useful model system for the study of pulmonary fibrosis, and the understanding of mechanisms of bleomycin signal transduction pathways should help in developing therapeutic strategies. 6 . Bleomycin activation of ARE-binding proteins is dependent upon reactive oxygen species (ROS) generation, but activation of NF-B is dependent upon extracellular signal-regulated kinase 1/2-mitogen-activated protein kinase (ERK1/2-MAPK). Confluent BPAEC were pretreated with 10 g/ml U-0126 or 20 mM N-acetylcysteine (NAC) for 30 min, then treated with 1 g/ml bleomycin for 30 min before preparation of nuclear extracts. EMSA experiments were performed as described. A: EMSA using ARE consensus oligonucleotide. B: EMSA using NF-B consensus oligonucleotide. Positions of specific bands are indicated. EMSAs with inhibitors were repeated at least 3 times. Densitometry of the NF-B band is shown above EMSA. C: total cellular RNA was extracted, and Northern blot analysis was performed as described for ␥-GCS heavy chain (␥-GCSh). Densitometric quantitation of ␥-GCSh mRNA was performed, and control levels were normalized between experiments. Data show the mean value (n ϭ 3, ϮSE).
